Pfizer reported Q3 earnings of $0.60 per share (versus $0.57 in Q3 FY 2014), beating analysts' consensus of $0.51.
The company's revenues amounted to $12.087 bln (-2.2% y/y), beating consensus estimate of $11.574 bln.
PFE rose to $35.10 (+2.75%) in pre-market trading.
